IN2009DN05670A - - Google Patents

Download PDF

Info

Publication number
IN2009DN05670A
IN2009DN05670A IN5670DEN2009A IN2009DN05670A IN 2009DN05670 A IN2009DN05670 A IN 2009DN05670A IN 5670DEN2009 A IN5670DEN2009 A IN 5670DEN2009A IN 2009DN05670 A IN2009DN05670 A IN 2009DN05670A
Authority
IN
India
Prior art keywords
carbolines
producing
intermediates
fused gamma
methods
Prior art date
Application number
Other languages
English (en)
Inventor
Charles Tomesch John
Li Peng
Yao Wei
Zhang Qiang
David Beard James
S Thompson Andrew
Cheng Hua
Original Assignee
Intra Cellular Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39759858&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2009DN05670(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intra Cellular Therapies Inc filed Critical Intra Cellular Therapies Inc
Publication of IN2009DN05670A publication Critical patent/IN2009DN05670A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/16Peri-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
IN5670DEN2009 2007-03-12 2008-03-12 IN2009DN05670A (cs)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90647307P 2007-03-12 2007-03-12
PCT/US2008/003340 WO2008112280A1 (en) 2007-03-12 2008-03-12 Substituted heterocycle fused gamma-carbolines synthesis

Publications (1)

Publication Number Publication Date
IN2009DN05670A true IN2009DN05670A (cs) 2015-07-24

Family

ID=39759858

Family Applications (1)

Application Number Title Priority Date Filing Date
IN5670DEN2009 IN2009DN05670A (cs) 2007-03-12 2008-03-12

Country Status (12)

Country Link
US (11) US8309722B2 (cs)
EP (2) EP2134710B1 (cs)
JP (7) JP5567349B2 (cs)
KR (7) KR101999300B1 (cs)
CN (2) CN101796051B (cs)
AU (5) AU2008226814C1 (cs)
CA (1) CA2679754C (cs)
DK (1) DK2134710T3 (cs)
ES (1) ES2776889T3 (cs)
IN (1) IN2009DN05670A (cs)
MX (3) MX2009009773A (cs)
WO (1) WO2008112280A1 (cs)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101796051B (zh) 2007-03-12 2013-11-06 细胞内治疗公司 与取代的杂环稠合的γ-咔啉的合成
WO2009089482A1 (en) 2008-01-11 2009-07-16 Albany Molecular Research, Inc. (1-azinone) -substituted pyridoindoles as mch antagonists
EP2262505B1 (en) 2008-03-12 2014-09-10 Intra-Cellular Therapies, Inc. Substituted heterocycle fused gamma-carbolines solid
CN105168219B (zh) 2008-05-27 2018-11-20 细胞内治疗公司 用于睡眠障碍和其他疾病的方法和组合物
US9107696B2 (en) * 2008-08-06 2015-08-18 Emory University Method of embryo transfer that eliminates transferred air while hormonally inducing implantation and apparatus
PA8843701A1 (es) 2008-09-29 2010-05-26 Abbott Lab Derivados de indolina y métodos para usarlos
US9625475B2 (en) 2008-09-29 2017-04-18 Abbvie Inc. Indole and indoline derivatives and methods of use thereof
US8618299B2 (en) 2009-07-01 2013-12-31 Albany Molecular Research, Inc. Azinone-substituted azapolycycle MCH-1 antagonists, methods of making, and use thereof
JP2012532144A (ja) 2009-07-01 2012-12-13 アルバニー モレキュラー リサーチ, インコーポレイテッド アジノン置換アゼピノ[b]インドールおよびピリド−ピロロ−アゼピンmch−1拮抗薬、ならびにその作製方法および使用
WO2011003007A1 (en) 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof
WO2011003021A1 (en) 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof
WO2011133224A1 (en) 2010-04-22 2011-10-27 Intra-Cellular Therapies, Inc. Organic compounds
WO2012088124A2 (en) 2010-12-21 2012-06-28 Albany Molecular Research, Inc. Tetrahydro-azacarboline mch-1 antagonists, methods of making, and uses thereof
US8697700B2 (en) 2010-12-21 2014-04-15 Albany Molecular Research, Inc. Piperazinone-substituted tetrahydro-carboline MCH-1 antagonists, methods of making, and uses thereof
WO2013155504A1 (en) * 2012-04-14 2013-10-17 Intra-Cellular Therapies, Inc. Novel methods
PT2968320T (pt) 2013-03-15 2021-01-28 Intra Cellular Therapies Inc Compostos orgânicos
KR102287288B1 (ko) * 2013-12-03 2021-08-06 인트라-셀룰라 써래피스, 인코퍼레이티드. 신규한 방법
MX2021014508A (es) 2014-04-04 2023-05-18 Intra Cellular Therapies Inc Gamma-carbolinas fusionadas con heterociclos sustituidas con deuterio.
US9745300B2 (en) 2014-04-04 2017-08-29 Intra-Cellular Therapies, Inc. Organic compounds
US10179776B2 (en) 2014-06-09 2019-01-15 Intra-Cellular Therapies, Inc. Compounds and methods of use to treat schizophrenia
US10118890B2 (en) 2014-10-10 2018-11-06 The Research Foundation For The State University Of New York Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration
CA2983992A1 (en) * 2015-04-30 2016-11-03 The Regents Of The University Of Colorado, A Body Corporate Polycyclic indoline and indolenine compounds
HUE053737T2 (hu) 2016-01-26 2021-07-28 Intra Cellular Therapies Inc Piridopirrolokinoxalin vegyületek, készítményeik és alkalmazásaik
ES2879888T3 (es) 2016-03-25 2021-11-23 Intra Cellular Therapies Inc Compuestos orgánicos y su uso en el tratamiento o prevención de trastornos del sistema nervioso central
EP3436455A4 (en) 2016-03-28 2019-09-04 Intra-Cellular Therapies, Inc. NOVEL SALTS AND CRYSTALS
US10682354B2 (en) 2016-03-28 2020-06-16 Intra-Cellular Therapies, Inc. Compositions and methods
JP6997718B2 (ja) * 2016-03-28 2022-01-18 イントラ-セルラー・セラピーズ・インコーポレイテッド 新規共結晶
PL3497104T3 (pl) 2016-08-09 2022-02-21 Teva Pharmaceuticals International Gmbh Postacie w stanie stałym soli ditosylanowej lumateperonu
WO2018064465A1 (en) 2016-09-29 2018-04-05 The Regents Of The University Of California Compounds for increasing neural plasticity
US11331316B2 (en) 2016-10-12 2022-05-17 Intra-Cellular Therapies, Inc. Amorphous solid dispersions
WO2018126140A1 (en) 2016-12-29 2018-07-05 Intra-Cellular Therapies, Inc. Organic compounds
WO2018126143A1 (en) 2016-12-29 2018-07-05 Intra-Cellular Therapies, Inc. Organic compounds
JP7132939B2 (ja) 2017-03-24 2022-09-07 イントラ-セルラー・セラピーズ・インコーポレイテッド 新規組成物および方法
CN110636845A (zh) 2017-04-10 2019-12-31 雷迪博士实验室有限公司 卢美哌隆对甲苯磺酸盐的无定形形式和固体分散体
CN111093664B (zh) 2017-07-26 2023-06-02 细胞内治疗公司 有机化合物
CN111093665A (zh) 2017-07-26 2020-05-01 细胞内治疗公司 有机化合物
WO2019067591A1 (en) * 2017-09-26 2019-04-04 Intra-Cellular Therapies, Inc. NEW SALTS AND CRYSTALS
WO2019102240A1 (en) 2017-11-27 2019-05-31 Egis Gyógyszergyár Zrt. Method for the manufacture of lumateperone and its salts
US11980617B2 (en) 2018-03-16 2024-05-14 Intra-Cellular Therapies, Inc. Methods of treating acute depression and/or acute anxiety
IL277509B2 (en) 2018-03-23 2023-11-01 Intra Cellular Therapies Inc Organic compounds
JP7462568B2 (ja) 2018-03-23 2024-04-05 イントラ-セルラー・セラピーズ・インコーポレイテッド 有機化合物
JP7476115B2 (ja) 2018-06-06 2024-04-30 イントラ-セルラー・セラピーズ・インコーポレイテッド 新規の塩および結晶
MX2020013335A (es) 2018-06-08 2021-05-27 Intra Cellular Therapies Inc Metodos novedosos.
KR102778034B1 (ko) * 2018-06-11 2025-03-12 인트라-셀룰라 써래피스, 인코퍼레이티드. 치환된 헤테로환 융합 감마-카르볼린 합성
BR112021001738A2 (pt) 2018-06-21 2021-06-29 Aquestive Therapeutics, Inc. sistema e método para fabricação de doses unitárias individuais personalizadas contendo ativos farmacêuticos
MA53219B1 (fr) 2018-08-13 2024-09-30 F. Hoffmann-La Roche Ag Nouveaux composés hétérocycliques en tant qu'inhibiteurs de monoacylglycérol lipase
WO2020047241A1 (en) 2018-08-29 2020-03-05 Intra-Cellular Therapies, Inc. Novel compositions and methods
JP7546546B2 (ja) 2018-08-31 2024-09-06 イントラ-セルラー・セラピーズ・インコーポレイテッド 新規方法
MX2021002321A (es) 2018-08-31 2021-04-28 Intra Cellular Therapies Inc Nuevos metodos.
CN112955124A (zh) 2018-09-07 2021-06-11 阿奎蒂夫疗法公司 具有精确的活性物溶出谱的口腔膜组合物和剂型
EP3887374A2 (en) 2018-11-27 2021-10-06 Teva Pharmaceuticals International GmbH Solid state forms of lumateperone salts and processes for preparation of lumateperone and salts thereof
MX2021007143A (es) 2018-12-17 2021-08-18 Intra Cellular Therapies Inc Sintesis de gamma-carbolinas fusionadas con heterociclo sustituido.
CN113423568A (zh) 2018-12-17 2021-09-21 细胞内治疗公司 有机化合物
KR20210104833A (ko) 2018-12-17 2021-08-25 인트라-셀룰라 써래피스, 인코퍼레이티드. 치환된 헤테로사이클 융합 감마-카르볼린 합성
EP3897621A4 (en) 2018-12-21 2022-09-07 Intra-Cellular Therapies, Inc. ORGANIC COMPOUNDS
JP7377871B2 (ja) 2018-12-21 2023-11-10 イントラ-セルラー・セラピーズ・インコーポレイテッド 有機化合物
EP3931189A4 (en) 2019-02-27 2022-11-30 The Regents Of The University Of California Azepino-indoles and other heterocycles for treating brain disorders
MX2022000143A (es) 2019-07-07 2022-02-17 Intra Cellular Therapies Inc Metodos novedosos.
JP2022549335A (ja) 2019-09-25 2022-11-24 イントラ-セルラー・セラピーズ・インコーポレイテッド 新規方法
WO2021087359A1 (en) 2019-11-01 2021-05-06 Aquestive Therapeutics, Inc. Prodrug compositions and methods of treatment
CN115038451A (zh) 2019-11-14 2022-09-09 阿奎斯蒂弗医疗股份有限公司 多模式组合物和治疗方法
CN110698474B (zh) * 2019-11-14 2021-11-02 福州大学 一种α位取代四氢-γ-咔啉类化合物及其制备方法和应用
WO2021119334A1 (en) 2019-12-11 2021-06-17 Intra-Cellular Therapies, Inc. Organic compound
EP4076461A4 (en) 2019-12-19 2024-01-03 Intra-Cellular Therapies, Inc. Methods of schizophrenia treatment
CN112062767B (zh) * 2020-10-20 2022-03-11 杭州科巢生物科技有限公司 一种卢美哌隆的制备方法及其中间体
CA3208345A1 (en) 2021-01-15 2022-07-21 Aquestive Therapeutics, Inc. Prodrug compositions and methods of treatment
US20220347117A1 (en) 2021-03-09 2022-11-03 Aquestive Therapeutics, Inc. Dosage forms having equivalent biocomparable profiles
CN113024554B (zh) * 2021-03-24 2023-03-14 上海法默生物科技有限公司 一种卢美哌隆中间体的制备方法
CN114105980B (zh) * 2021-12-13 2024-04-16 南方科技大学坪山生物医药研究院 卢美哌隆中间体化合物的制备方法及卢美哌隆中间体化合物
CN114105985B (zh) * 2021-12-13 2024-04-16 南方科技大学坪山生物医药研究院 不对称氢化构建卢美哌隆中间体的方法及卢美哌隆中间体
CA3239565A1 (en) 2021-12-15 2023-06-22 Delix Therapeutics, Inc. Phenoxy and benzyloxy substituted psychoplastogens and uses thereof
US12414948B2 (en) 2022-05-18 2025-09-16 Intra-Cellular Therapies, Inc. Methods
EP4642458A1 (en) 2022-12-30 2025-11-05 Intra-Cellular Therapies, Inc. Heterocycle fused gamma-carbolines acting on the serotonine 5-ht2a receptor
WO2024173901A1 (en) 2023-02-17 2024-08-22 Intra-Cellular Therapies, Inc. Lumateperone and derivatives thereof for modulating the nervous system
WO2025223504A1 (zh) * 2024-04-26 2025-10-30 浙江奥翔药业股份有限公司 卢美哌隆中间体及其制备方法
WO2025240804A1 (en) 2024-05-16 2025-11-20 Intra-Cellular Therapies, Inc. Novel compositions, devices and methods
CN119912455B (zh) * 2025-01-22 2025-09-23 成都臻拓医药科技有限公司 一种卢美哌隆中间体化合物的制备方法

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US38679A (en) 1863-05-26 Improvement in water-elevators
US471A (en) 1837-11-20 Mode of
US6713A (en) 1849-09-11 Hobse-poweb
US39680A (en) 1863-08-25 Improvement in machines for breaking and cleaning flax
US2490813A (en) * 1944-11-29 1949-12-13 Standard Oil Co Continuous process for making aryl amines
US3299078A (en) * 1962-10-01 1967-01-17 Smith Kline French Lab Pyrido [3', 4': 4, 5] pyrrolo [3, 2, 1-hi] indoles and-[3, 2, 1-ij] quinolines
US3813392A (en) * 1969-06-09 1974-05-28 J Sellstedt Pyrrolo(1,2,3-alpha epsilon)quinoxalin-2(3h)-ones and related compounds
US3914421A (en) * 1972-06-19 1975-10-21 Endo Lab Pyridopyrrolobenzheterocycles for combatting depression
US4115577A (en) * 1972-06-19 1978-09-19 Endo Laboratories, Inc. Pyridopyrrolobenzheterocycles
US4183936A (en) * 1972-06-19 1980-01-15 Endo Laboratories, Inc. Pyridopyrrolobenzheterocycles
US4238607A (en) * 1972-06-19 1980-12-09 Endo Laboratories Inc. Pyridopyrrolo benzheterocycles
US4219550A (en) * 1978-11-09 1980-08-26 E. I. Du Pont De Nemours And Company Cis- and trans- octahydropyridopyrrolobenzheterocycles
US4522944A (en) * 1982-12-23 1985-06-11 Erba Farmitalia Carboxamido-derivatives of 5H-1,3,4-thiadiazolo[3,2-a]pyrimidines, compositions and use
EP0238059B1 (en) * 1986-03-19 1993-06-16 Kumiai Chemical Industry Co., Ltd. 5H-1,3,4-Thiazole[3,2-a]pyrimidin-5-one derivatives and fungicidal compositions containing the same
ES2058069T3 (es) * 1986-04-07 1994-11-01 Kumiai Chemical Industry Co Derivados de 5h-1,3,4-tiadiazolo-(3,2-a)-pirimidin-5-ona y nuevo compuesto fungicida agricola-horticola que contiene dicho derivado.
US5576460A (en) * 1994-07-27 1996-11-19 Massachusetts Institute Of Technology Preparation of arylamines
US5648539A (en) * 1996-02-29 1997-07-15 Xerox Corporation Low temperature arylamine processes
US5648542A (en) * 1996-02-29 1997-07-15 Xerox Corporation Arylamine processes
US5654482A (en) * 1996-02-29 1997-08-05 Xerox Corporation Triarylamine processes
US5847166A (en) 1996-10-10 1998-12-08 Massachusetts Institute Of Technology Synthesis of aryl ethers
US5723669A (en) 1997-01-30 1998-03-03 Xerox Corporation Arylamine processes
US5705697A (en) * 1997-01-30 1998-01-06 Xerox Corporation Arylamine processes
US5723671A (en) * 1997-01-30 1998-03-03 Xerox Corporation Arylamine processes
US6323366B1 (en) * 1997-07-29 2001-11-27 Massachusetts Institute Of Technology Arylamine synthesis
GB2328686B (en) * 1997-08-25 2001-09-26 Sankio Chemical Co Ltd Method for producing arylamine
WO1999018057A1 (en) * 1997-10-06 1999-04-15 Massachusetts Institute Of Technology Preparation of diaryl ether by condensation reactions
ATE229499T1 (de) 1998-02-26 2002-12-15 Massachusetts Inst Technology Metallkatalysierte arylierungen und vinylierungen von hydrazinen, hydrazonen, hydroxylaminen und oximen
US6235936B1 (en) * 1998-02-26 2001-05-22 Massachusetts Institute Of Technology Metal-catalyzed arylations of hydrazines, hydrazones, and related substrates
US5902901A (en) * 1998-05-07 1999-05-11 Xerox Corporation Arylamine processes
US7223879B2 (en) * 1998-07-10 2007-05-29 Massachusetts Institute Of Technology Ligands for metals and improved metal-catalyzed processes based thereon
JP5035813B2 (ja) 1998-07-10 2012-09-26 マサチューセッツ インスティテュート オブ テクノロジー 金属用のリガンドおよびそれらに基づいて改善された金属触媒法
US6395916B1 (en) * 1998-07-10 2002-05-28 Massachusetts Institute Of Technology Ligands for metals and improved metal-catalyzed processes based thereon
US6307087B1 (en) * 1998-07-10 2001-10-23 Massachusetts Institute Of Technology Ligands for metals and improved metal-catalyzed processes based thereon
US20010008942A1 (en) * 1998-12-08 2001-07-19 Buchwald Stephen L. Synthesis of aryl ethers
AR023574A1 (es) 1999-04-23 2002-09-04 Pharmacia & Upjohn Co Llc Compuestos de azepinindol tetraciclico,composiciones farmaceuticas y el uso de dichos compuestos para preparar un medicamento, e intermediarios
US6407092B1 (en) * 1999-04-23 2002-06-18 Pharmacia & Upjohn Company Tetracyclic azepinoindole compounds
US6713471B1 (en) * 1999-06-15 2004-03-30 Bristol-Myers Squibb Pharma Company Substituted heterocycle fused gamma-carbolines
IL147108A0 (en) * 1999-06-15 2002-08-14 Du Pont Pharm Co Substituted heterocycle fused gamma-carbolines
US7071186B2 (en) * 1999-06-15 2006-07-04 Bristol-Myers Squibb Pharma Co. Substituted heterocycle fused gamma-carbolines
US6541639B2 (en) * 2000-07-26 2003-04-01 Bristol-Myers Squibb Pharma Company Efficient ligand-mediated Ullmann coupling of anilines and azoles
US6849619B2 (en) * 2000-12-20 2005-02-01 Bristol-Myers Squibb Company Substituted pyridoindoles as serotonin agonists and antagonists
US6699852B2 (en) * 2000-12-20 2004-03-02 Bristol-Myers Squibb Pharma Company Substituted pyridoindoles as serotonin agonists and antagonists
CN1854128B (zh) 2001-04-24 2012-05-16 麻省理工学院 铜-催化的碳-杂原子键和碳-碳键的形成
US6849640B2 (en) * 2001-08-08 2005-02-01 Pharmacia & Upjohn Company Therapeutic 1H-pyrido [4,3-b] indoles
US6888032B2 (en) * 2002-08-02 2005-05-03 Massachusetts Institute Of Technology Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds
US7223870B2 (en) 2002-11-01 2007-05-29 Pfizer Inc. Methods for preparing N-arylated oxazolidinones via a copper catalyzed cross coupling reaction
AU2003303210A1 (en) * 2002-12-19 2004-07-14 Bristol-Myers Squibb Company Substituted tricyclic gamma-carbolines as serotonin receptor agonists and antagonists
JP2005259113A (ja) 2004-02-12 2005-09-22 Ricoh Co Ltd プロセス編集装置、プロセス管理装置、プロセス編集プログラム、プロセス管理プログラム、記録媒体、プロセス編集方法及びプロセス管理方法
US7592454B2 (en) * 2004-04-14 2009-09-22 Bristol-Myers Squibb Company Substituted hexahydro-pyridoindole derivatives as serotonin receptor agonists and antagonists
KR100883003B1 (ko) * 2004-12-15 2009-02-12 에프. 호프만-라 로슈 아게 알츠하이머병의 치료를 위한 글라이신 수송체1(glyt-1) 억제제로서 바이- 및 트라이사이클릭 치환된페닐 메탄온
CN101796051B (zh) * 2007-03-12 2013-11-06 细胞内治疗公司 与取代的杂环稠合的γ-咔啉的合成
EP2262505B1 (en) 2008-03-12 2014-09-10 Intra-Cellular Therapies, Inc. Substituted heterocycle fused gamma-carbolines solid
CN105168219B (zh) 2008-05-27 2018-11-20 细胞内治疗公司 用于睡眠障碍和其他疾病的方法和组合物
US8309772B2 (en) 2008-07-31 2012-11-13 Celanese International Corporation Tunable catalyst gas phase hydrogenation of carboxylic acids
WO2011133224A1 (en) 2010-04-22 2011-10-27 Intra-Cellular Therapies, Inc. Organic compounds
WO2013155504A1 (en) 2012-04-14 2013-10-17 Intra-Cellular Therapies, Inc. Novel methods
PT2968320T (pt) 2013-03-15 2021-01-28 Intra Cellular Therapies Inc Compostos orgânicos
KR102287288B1 (ko) 2013-12-03 2021-08-06 인트라-셀룰라 써래피스, 인코퍼레이티드. 신규한 방법
MX2021014508A (es) 2014-04-04 2023-05-18 Intra Cellular Therapies Inc Gamma-carbolinas fusionadas con heterociclos sustituidas con deuterio.
ES2879888T3 (es) 2016-03-25 2021-11-23 Intra Cellular Therapies Inc Compuestos orgánicos y su uso en el tratamiento o prevención de trastornos del sistema nervioso central
WO2019102240A1 (en) 2017-11-27 2019-05-31 Egis Gyógyszergyár Zrt. Method for the manufacture of lumateperone and its salts

Also Published As

Publication number Publication date
MX394214B (es) 2025-03-24
MX2022008904A (es) 2022-08-16
US10221176B2 (en) 2019-03-05
KR20210038731A (ko) 2021-04-07
AU2008226814B2 (en) 2014-03-27
CN101796051B (zh) 2013-11-06
KR101805914B1 (ko) 2017-12-06
US20140364609A1 (en) 2014-12-11
JP5567349B2 (ja) 2014-08-06
US20250101022A1 (en) 2025-03-27
US20180044337A1 (en) 2018-02-15
MX2020001497A (es) 2020-03-12
AU2016234905B2 (en) 2018-03-29
KR102372149B1 (ko) 2022-03-07
US11066407B2 (en) 2021-07-20
KR20200047755A (ko) 2020-05-07
KR20150140397A (ko) 2015-12-15
KR20180074802A (ko) 2018-07-03
KR20190053975A (ko) 2019-05-20
CA2679754A1 (en) 2008-09-18
JP2019147819A (ja) 2019-09-05
MX2009009773A (es) 2009-12-16
CN101796051A (zh) 2010-08-04
US20160194326A1 (en) 2016-07-07
WO2008112280A1 (en) 2008-09-18
JP5918306B2 (ja) 2016-05-18
JP2016155849A (ja) 2016-09-01
KR101981840B1 (ko) 2019-05-23
AU2019229334A1 (en) 2019-10-03
AU2008226814C1 (en) 2014-11-20
ES2776889T3 (es) 2020-08-03
KR101999300B1 (ko) 2019-07-12
DK2134710T3 (da) 2020-05-18
CA2679754C (en) 2018-08-07
US12139490B2 (en) 2024-11-12
EP2134710B1 (en) 2020-02-12
CN103626766B (zh) 2017-06-09
AU2016234905A1 (en) 2016-10-20
KR20100014428A (ko) 2010-02-10
KR20190083009A (ko) 2019-07-10
JP6231151B2 (ja) 2017-11-15
JP6773837B2 (ja) 2020-10-21
CN103626766A (zh) 2014-03-12
AU2018201818A1 (en) 2018-04-05
EP3663294A1 (en) 2020-06-10
US20200115380A1 (en) 2020-04-16
KR102107954B1 (ko) 2020-05-07
US20220332716A1 (en) 2022-10-20
US10464938B2 (en) 2019-11-05
KR102065319B1 (ko) 2020-01-10
AU2018201818B2 (en) 2019-06-20
EP2134710A4 (en) 2011-09-28
JP2014208676A (ja) 2014-11-06
US20100113781A1 (en) 2010-05-06
US20190292185A1 (en) 2019-09-26
US8779139B2 (en) 2014-07-15
US20200087305A1 (en) 2020-03-19
US11407751B2 (en) 2022-08-09
AU2008226814A1 (en) 2008-09-18
JP2018035189A (ja) 2018-03-08
AU2014203483B2 (en) 2016-06-30
JP6522710B2 (ja) 2019-05-29
JP2022180440A (ja) 2022-12-06
AU2019229334B2 (en) 2020-09-17
US20130046097A1 (en) 2013-02-21
US20190218219A1 (en) 2019-07-18
EP2134710A1 (en) 2009-12-23
JP2021006559A (ja) 2021-01-21
US8309722B2 (en) 2012-11-13
AU2014203483A1 (en) 2014-07-17
US9315504B2 (en) 2016-04-19
KR102238390B1 (ko) 2021-04-08
JP2010521464A (ja) 2010-06-24
US10597395B2 (en) 2020-03-24
US9751883B2 (en) 2017-09-05

Similar Documents

Publication Publication Date Title
IN2009DN05670A (cs)
TW200604184A (en) Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
PH12013502230A1 (en) Multispecific antibodies
MX345909B (es) Anticuerpos anti-fgfr3 y métodos que los utilizan.
MY181898A (en) Heterocyclic compounds and uses thereof
TN2011000673A1 (en) Bace inhibitors
MX2011001679A (es) Derivados de flavina.
MX2010004374A (es) Armazones proteinicos.
PH12012501346A1 (en) Heteroaryl compounds and uses thereof
MX2011010012A (es) NUEVOS ANTICUERPOS ANTI-A5ß1 Y SUS USOS.
MY152749A (en) Pyrazole and fused pyrazole glucokinase activators
SG179085A1 (en) Pi3 kinase inhibitors and uses thereof
MX2009008430A (es) Anticuerpos anti-robo4 y sus usos.
MY170720A (en) Antibody formulations
CA2705357C (en) Formulations for taci-immunoglobulin fusion proteins
MX2012002387A (es) Aminas de triazol fusionadas como moduladores p2x7.
UA104438C2 (uk) Спосіб одержання дабігатрану і його проміжних сполук
PH12013500500A1 (en) Fused heteroaryls and their uses
TW200624426A (en) BACE inhibitors
WO2009015037A3 (en) 5-pyridinone substituted indazoles
MX2009004030A (es) Articulos antimicrobianos y metodos de fabricacion.
PH12013502194A1 (en) Antibodies to egfl7 and methods for their use
TW200738751A (en) Anti-EphrinB2 antibodies and methods using same
WO2008085900A3 (en) Methods for generating novel stabilized proteins
IL200000A (en) Process for Preparing 5- (1- Alkylthio) Alkylpyridines are Stored in Position 2 and Its Compounds